Abstract
Several imaging modalities to diagnose cancer, which include computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, optical imaging, and gamma scintigraphy, have been previously used. For instance, CT and MRI provide considerable anatomic information about the location and the extent of tumors, but do not adequately differentiate residual or recurrent tumors from edema, radiation necrosis, or gliosis. On the other ultrasound images provide limited information about local and regional morphology with blood flow. Similarly optical imaging showed promising results, but did not demonstrate the ability to detect deep tissue penetration. Notably, radionuclide imaging modalities are diagnostic cross-sectional imaging techniques that map the location and concentration of radionuclide-labeled compounds. Moreover, molecular imaging agents are making it possible to “see” the molecular makeup of the tumor and its metabolic activity beyond tumor location, size, shape, and viability. Other technological limitations include nuclear images, which can provide a very accurate definition of metabolically active areas, but miss anatomic features. As a result, new imaging modalities have combined nuclear images with CT scans for treatment planning. The hybrid scanners combine anatomic and functional images taken during a single procedure, without having to reposition the patient between scans. In this chapter, multiple ligands beyond clinical standard 18F-fluorodexoyglucose are reviewed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Rubi S, Costes N, Heckemann RA, et al. Positron emission tomography with alpha-[11C]methyl-L-tryptophan in tuberous sclerosis complex-related epilepsy. Epilepsia. 2013;54(12):2143–50.
Park HK, Kim JS, Im KC, Kim MJ, Lee JH, Lee MC, Kim J, Chung SJ. Visual hallucinations and cognitive impairment in Parkinson’s disease. Can J Neurol Sci 2013;40(5):657–662.
Bertelson JA, Ajtai B. Neuroimaging of dementia. Neurol Clin. 2014;32(1):59–93.
Chetelat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F, Vandenberghe R. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. Neuroimage Clin. 2013;2:356–65.
Lehner S, Uebleis C, Schussler F, et al. The amount of viable and dyssynchronous myocardium is associated with response to cardiac resynchronization therapy: initial clinical results using multiparametric ECG-gated [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2013;40(12):1876–83.
Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004;45(1):85–92.
Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000;30(3):150–85.
Plowman PN, Saunders CA, Maisey M. On the usefulness of brain PET scanning to the paediatric neuro-oncologist. Br J Neurosurg. 1997;11(6):525–32.
Weber WA, Avril N, Schwaiger M. Relevance of Positron Emission Tomography (PET) in oncology. Strahlenther Onkol. 1999;175(8):356–73.
Lau CL, Jr Harpole DH, Patz E. Staging techniques for lung cancer. Chest Surg Clin N Am. 2000;10(4):781–801.
Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med. 2000;41(10):1695–701.
Yutani K, Shiba E, Kusuoka H, Tatsumi M, Uehara T, Taguchi T, Takai SI, Nishimura T. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr. 2000;24(2):274–80.
Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med. 2000;27(9):1305–11.
Folpe AL, Lyles RH, Sprouse JT, Conrad ER, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6(4):1279–87.
Meyer PT, Spetzger U, Mueller HD, Zeggel T, Sabri O, Schreckenberger M. High F-18 FDG uptake in a low-grade supratentorial ganglioma: a positron emission tomography case report. Clin Nucl Med. 2000;25(9):694–7.
Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25(11):874–81.
Carretta A, Landoni C, Melloni G, Ceresoli GL, Compierchio A, Fazio F, Zannini P. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases – a pilot study. Eur J Cardiothorac Surg. 2000;17(4):377–83.
Torre W, Garcia-Velloso MJ, Galbis J, Fernandez O, Richter J. FDG-PET detection of primary lung cancer in a patient with an isolated cerebral metastasis. J Cardiovasc Surg. 2000;41(3):503–5.
Brunelle F. Noninvasive diagnosis of brain tumours in children. Childs Nerv Syst. 2000;16(10–11):731–4.
Mankoff DA, Dehdashti F, Shields AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia. 2000;2(1–2):71–88.
Fitzgerald J, Parker JA, Danias PG. F-18 fluoro deoxyglucose SPECT for assessment of myocardial viability. J Nucl Cardiol. 2000;7(4):382–7.
Schwarz A, Kuwert T. Nuclear medicine diagnosis in diseases of the central nervous system. Radiologe. 2000;40(10):858–62.
Roelcke U, Leenders KL. PET in neuro-oncology. J Cancer Res Clin Oncol. 2001;127(1):2–8.
Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev. 2008;27(4):545–54.
Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47(5):885–95.
Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake–the role of PET/CT. Eur Radiol. 2006;16(5):1054–65.
Brock CS, Meikle SR, Price P. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? Eur J Nucl Med. 1997;24(6):691–705.
Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, Im JG. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7(1):57–69.
Yang DJ, Kim CG, Schechter NR, et al. Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology. 2003;226(2):465–73.
Schechter NR, Erwin WD, Yang DJ, et al. Radiation dosimetry and biodistribution of (99 m)Tc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2009;36(10):1583–91.
Zhang YH, Bryant J, Kong FL, Yu DF, Mendez R, Edmund KE, Yang DJ. Molecular imaging of mesothelioma with (99 m)Tc-ECG and (68)Ga-ECG. J Biomed Biotechnol. 2012;2012:232863.
Yang DJ, Kong FL, Oka T, Bryant JL. Molecular imaging kits for hexosamine biosynthetic pathway in oncology. Curr Med Chem. 2012;19(20):3310–4.
Hanover JA, Krause MW, Love DC. The hexosamine signaling pathway: O-GlcNAc cycling in feast or famine. Biochim Biophys Acta. 2010;1800(2):80–95.
Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem. 2011;80:825–58.
Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-Linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 2012;287(14):11070–81.
Krzeslak A, Forma E, Bernaciak M, Romanowicz H, Brys M. Gene expression of O-GlcNAc cycling enzymes in human breast cancers. Clin Exp Med. 2012;12(1):61–5.
Ozcan S, Andrali SS, Cantrell JE. Modulation of transcription factor function by O-GlcNAc modification. Biochim Biophys Acta. 2010;1799(5–6):353–64.
Lewis BA, Hanover JA. O-GlcNAc and the epigenetic regulation of gene expression. J Biol Chem. 2014;289(50):34440–8.
Golks A, Tran TT, Goetschy JF, Guerini D. Requirement for O-linked N-acetylglucosaminyltransferase in lymphocytes activation. EMBO J. 2007;26(20):4368–79.
Pham LV, Tamayo AT, Yoshimura LC, Lin-Lee YC, Ford RJ. Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood. 2005;106(12):3940–7.
Urakami T, Sakai K, Asai T, Fukumoto D, Tsukada H, Oku N. Evaluation of O-[(18)F]fluoromethyl-D-tyrosine as a radiotracer for tumor imaging with positron emission tomography. Nucl Med Biol. 2009;36(3):295–303.
Langen KJ, Muhlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen HH. Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl]-L-methionine. J Nucl Med. 2000;41(7):1250–5.
Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, Blasberg R. “Facilitated” amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab. 1998;18(5):500–9.
Syrota A, Comar D, Cerf M, Plummer D, Maziere M, Kellershohn C. [11C]methionine pancreatic scanning with positron emission computed tomography. J Nucl Med. 1979;20(7):778–81.
Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry. 1999;46(5):681–8.
Kersemans K, Bauwens M, Mertens J. Method for stabilizing non carrier added 2-[(18)F]fluoromethyl-l-phenylalanine, a new tumour tracer, during radiosynthesis and radiopharmaceutical formulation. Nucl Med Biol. 2008;35(4):425–32.
Inoue T, Shibasaki T, Oriuchi N, et al. 18F alpha-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med. 1999;40(3):399–405.
Kaira K, Oriuchi N, Otani Y, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13(21):6369–78.
Yamaura G, Yoshioka T, Fukuda H, Yamaguchi K, Suzuki M, Furumoto S, Iwata R, Ishioka C. O-[18F]fluoromethyl-L-tyrosine is a potential tracer for monitoring tumour response to chemotherapy using PET: an initial comparative in vivo study with deoxyglucose and thymidine. Eur J Nucl Med Mol Imaging. 2006;33(10):1134–9.
Langen KJ, Pauleit D, Coenen HH. 3-[(123)I]Iodo-alpha-methyl-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2002;29(6):625–31.
Ali MS, Kong FL, Rollo A, Mendez R, Kohanim S, Smith DL, Yang DJ. Development of (99 m)Tc-N4-NIM for molecular imaging of tumor hypoxia. J Biomed Biotechnol. 2012;2012:828139.
Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61(4):729–37.
Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514(2):291–302.
del AE, Urtti A, Yliperttula M. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 2008;35(3):161–174.
Tisljar U, Kloster G, Ritzl F, Stocklin G. Accumulation of radioiodinated L-alpha-methyltyrosine in pancreas of mice: concise communication. J Nucl Med. 1979;20(9):973–6.
Kloss G, Leven M. Accumulation of radioiodinated tyrosine derivatives in the adrenal medulla and in melanomas. Eur J Nucl Med. 1979;4(3):179–86.
Langen KJ, Coenen HH, Roosen N, et al. SPECT studies of brain tumors with L-3-[123I] iodo-alpha-methyl tyrosine: comparison with PET, 124IMT and first clinical results. J Nucl Med. 1990;31(3):281–6.
Kong FL, Zhang Y, Young DP, Yu DF, Yang DJ. Development of (99 m)Tc-EC-tyrosine for early detection of breast cancer tumor response to the anticancer drug melphalan. Acad Radiol. 2013;20(1):41–51.
Kong FL, Zhang Y, Ali MS, et al. Synthesis of (99 m)Tc-EC-AMT as an imaging probe for amino acid transporter systems in breast cancer. Nucl Med Commun. 2010;31(8):699–707.
Kong FL, Ali MS, Zhang Y, Oh CS, Yu DF, Chanda M, Yang DJ. Synthesis and evaluation of amino acid-based radiotracer 99mTc-N4-AMT for breast cancer imaging. J Biomed Biotechnol. 2011;2011:276907.
Yoshida Y, Kurokawa T, Sawamura Y, Shinagawa A, Okazawa H, Fujibayashi Y, Kotsuji F. The positron emission tomography with F18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol Oncol. 2007;104(3):764–6.
Takahashi N, Yang DJ, Kurihara H, Borne A, Kohanim S, Oh CS, Mawlawi O, Kim EE. Functional imaging of estrogen receptors with radiolabeled-GAP-EDL in rabbit endometriosis model. Acad Radiol. 2007;14(9):1050–7.
Yang DJ, Li C, Kuang LR, et al. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci. 1994;55(1):53–67.
Brown JM. The hypoxic cell: a target for selective cancer therapy–eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999;59(23):5863–70.
Chu T, Li R, Hu S, Liu X, Wang X. Preparation and biodistribution of technetium-99 m-labeled 1-(2-nitroimidazole-1-yl)-propanhydroxyiminoamide (N2IPA) as a tumor hypoxia marker. Nucl Med Biol. 2004;31(2):199–203.
Seddon BM, Maxwell RJ, Honess DJ, Grimshaw R, Raynaud F, Tozer GM, Workman P. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin Cancer Res. 2002;8(7):2323–35.
Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9(12):674–87.
Hara T, Kosaka N, Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43(2):187–99.
DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42(12):1805–14.
Szyszko TA, Yip C, Szlosarek P, Goh V, Cook GJ. The role of new PET tracers for lung cancer. Lung Cancer-J Iaslc. 2016;94:7–14.
Gambhir SS, Barrio JR, Phelps ME, et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci U S A. 1999;96(5):2333–8.
Alauddin MM, Shahinian A, Kundu RK, Gordon EM, Conti PS. Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors. Nucl Med Biol. 1999;26(4):371–6.
Yaghoubi S, Barrio JR, Dahlbom M, et al. Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med. 2001;42(8):1225–34.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Song, SL., Li, PL., Huang, G. (2017). PET Radiopharmaceuticals in Oncology Beyond FDG. In: Inoue, T., Yang, D., Huang, G. (eds) Personalized Pathway-Activated Systems Imaging in Oncology. Springer, Singapore. https://doi.org/10.1007/978-981-10-3349-0_12
Download citation
DOI: https://doi.org/10.1007/978-981-10-3349-0_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-3348-3
Online ISBN: 978-981-10-3349-0
eBook Packages: MedicineMedicine (R0)